Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16103859 | 0.85 | KMT2A (0.60) | KMT2AHTTMEN1HTR1ATDP1 | |
| SCHEMBL13779927 | 0.85 | KMT2A (0.59) | KMT2AHTTMEN1ALDH1A1TSHR | |
| SCHEMBL10272740 | 0.83 | TDP1 (0.62) | KMT2AHTTMEN1HTR1ATDP1 | |
| SCHEMBL12800844 | 0.83 | KMT2A (0.83) | KMT2AHTTMEN1TDP1CYP1A2 | |
| SCHEMBL13674468 | 0.83 | KMT2A (0.83) | KMT2AHTTMEN1TDP1KDM4E | |
| SCHEMBL4534029 | 0.83 | KMT2A (0.83) | KMT2AHTTMEN1TDP1KDM4E | |
| SCHEMBL13472629 | 0.82 | KMT2A (0.61) | KMT2AHTTMEN1ALDH1A1POLB | |
| Citric Acid SCHEMBL4740036 | 0.82 | KDM4E (0.62) | KMT2AHTTMEN1HTR1ATDP1 | |
| SCHEMBL19741751 | 0.82 | — | — | |
| SCHEMBL965286 | 0.82 | KMT2A (0.82) | KMT2AHTTALDH1A1NPC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| EP-1963331-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20230265083-A1 | Heterocycle CDK Inhibitors And Their Use Thereof | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-24 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2022056449-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021050824-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-7157473-B2 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157473-B2 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1450821-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | Intercell AG (AT) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003047602-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | INTERCELL AG (AT) | 2003-06-12 | — | — | WO | disclosed |
| EP-0259113-B1 | CONTROLLED RELEASE DEVICE FOR AN ACTIVE SUBSTANCE | PFIZER INC. (US) | 1990-10-31 | — | — | EP | disclosed |
| EP-0300960-A2 | Pharmaceutical compositions and lactosyl compounds, and their preparation | Solco Basel AG (CH) | 1989-01-25 | — | — | EP | disclosed |
| US-4147785-A | Method for the treatment of onchocerciasis | Dobbie, Graham J. (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | KMT2A 282/4885HTT 2933/4885MEN1 2119/4885 |
| US-20230265083-A1 | Heterocycle CDK Inhibitors And Their Use Thereof | CDK3, CDK8, CDK9 | KMT2A 338/4885HTT 1938/4885MEN1 2253/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | KMT2A 551/4885HTT 3929/4885MEN1 2601/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | KMT2A 646/4885HTT 3827/4885MEN1 2421/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | KMT2A 282/4885HTT 2933/4885MEN1 2119/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KMT2A 3803/4885HTT 1294/4885MEN1 4292/4885 |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | KMT2A 4612/4885HTT 4543/4885MEN1 1728/4885 |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | CDK6, CDK3, CDK9 | KMT2A 282/4885HTT 2933/4885MEN1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.